Table 2.
Variables and responses for RLX-EMLs experimental runs prepared based on a 4131 factorial design.
| Trial Number | Run Order | Variables Levels | Mean Responses ± SD | ||||
|---|---|---|---|---|---|---|---|
| X1:PL:SL | X2:SL Type | Y1:VS (nm) | Y2:ZP (mV) | Y3:EE (%) | Y4:RE (%) | ||
| 1 | EML-6 | 1:1 | Tristearin | 106.0 ± 3.8 | −15.6 ± 0.3 | 87.2 ± 3.3 | 72.7 ± 3.1 |
| 2 | EML-7 | 2:1 | Tristearin | 160.9 ± 5.2 | −16.3 ± 0.6 | 91.2 ± 3.9 | 64.7 ± 3.7 |
| 3 | EML-2 | 3:1 | Tristearin | 206.2 ± 5.6 | −17.1 ± 0.4 | 95.3 ± 4.8 | 58.2 ± 2.9 |
| 4 | EML-12 | 4:1 | Tristearin | 236.2 ± 8.6 | −18.6 ± 0.7 | 98.9 ± 4.9 | 42.7 ± 1.8 |
| 5 | EML-4 | 1:1 | Tripalmitin | 97.2 ± 1.8 | −15.4 ± 0.6 | 85.5 ± 2.8 | 75.9 ± 3.2 |
| 6 | EML-9 | 2:1 | Tripalmitin | 137.0 ± 5.2 | −16.7 ± 0.6 | 90.4 ± 3.8 | 66.9 ± 2.9 |
| 7 | EML-5 | 3:1 | Tripalmitin | 192.2 ± 5.1 | −17.1 ± 0.2 | 93.1 ± 2.7 | 60.9 ± 2.4 |
| 8 | EML-10 | 4:1 | Tripalmitin | 223.2 ± 8.7 | −17.9 ± 0.8 | 98.2 ± 4.6 | 49.3 ± 2.3 |
| 9 | EML-1 | 1:1 | Compritol | 119.1 ± 3.3 | −16.1 ± 0.6 | 89.2 ± 3.1 | 71.2 ± 3.3 |
| 10 | EML-3 | 2:1 | Compritol | 174.9 ± 4.2 | −15.9 ± 0.3 | 91.9 ± 3.9 | 63.2 ± 2.7 |
| 11 | EML-11 | 3:1 | Compritol | 215.3± 9.3 | −16.8 ± 0.5 | 96.8 ± 4.1 | 53.1 ± 2.1 |
| 12 | EML-8 | 4:1 | Compritol | 247.1 ± 9.8 | −18.9 ± 0.7 | 99.1 ± 4.1 | 41.6 ± 1.9 |
RLX-EMLs, raloxifene hydrochloride emulsomes; PL:SL, lipoid: solid lipid weight ratio; SL type: solid lipid type; VS, vesicle size; ZP, zeta potential; EE, entrapment efficiency; RE, release efficiency after 6 h; SD, standard deviation.